N/A N=67 Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes
Asthma
Primary: Absolute Change in Morning Peak Flow — -15.7; 8.4; -5.6; -14.4 L/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=160 A Clinical Evaluation of PROPEL® Contour Sinus Implant
Chronic Rhinosinusitis (Diagnosis)
Primary: Difference in FSO Patency by Blinded Reviewer — 16.54; 12.36 mm^2 — p=0.059
Phase 2 N=89 A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
Postoperative Nausea and Vomiting (PONV)
Primary: Percentage of Participants With Complete Response in the Immediate Postoperative Period — 48.8; 71.8 percentage of participants
N/A N=15 A Single Arm Pilot Study of Pulsed Field Ablation in the Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Occurence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events — 0 Participants
Phase 3 N=1,971 Immune Modulators for Treating COVID-19
Covid19
Primary: Number of Participants Who Had Recovered by Day 28 — 421; 405; 414; 397 Participants — p=0.0793
N/A N=305 Efficacy of Two Novel Behavioral Post-cessation Weight Gain Interventions
Weight Change, Body · Smoking Cessation
Primary: Weight — -0.24; -1.11; 1.25 kilograms
Phase 2 N=20 A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
Atopic Dermatitis
Primary: Nemolizumab Serum Concentrations at Week 1-2 — 6478.8 nanogram per milliliter (ng/mL)
N/A N=28 Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment
Stroke
Primary: Change in Accuracy of Naming Untrained Pictures (Philadelphia Naming Test:PNT) Pre-treatment to Post-treatment — 5.76; 1.88 score on a scale — p=0.24
Phase 2 N=142 FX-322 in Adults With Acquired Sensorineural Hearing Loss
Hearing Loss, Sensorineural · Noise Induced Hearing Loss · Sudden Hearing Loss
Primary: Word Recognition in Quiet — 14.7; 11.1 Percent of subjects — p=0.525
Phase 3 N=666 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1 — 58.2; 51.3; 26.3; 20.0 Percentage of participants
Phase 2 N=147 The Effect of RNS60 on ALS Biomarkers
Amyotrophic Lateral Sclerosis
Primary: Pharmacodynamic Biomarkers: MCP-1 On-treatment Period Variation — 4.6; 2.2 pg/ml — p=0.6346
Phase 2 N=60 MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
Malignant Neoplasm · Oral Pain · Stomatitis
Primary: Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool — 1.69; 5.2; 4.54; 5.15…
N/A N=6 Feasibility Electrical Stimulation Study for Visual Hallucinations
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Steady State Visual Evoked Potential (ssVEP) — 1.725; 1.160; 1.180; 1.005 microvolts — p=0.10
Phase 3 N=1,000 A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
Rabies · Communicable Disease · Virus Diseases
Primary: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8 — 4.346; 0.232 IU/mL
Phase 2 N=41 Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
Ovarian Neoplasm
Primary: Confirmed Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 17.9 Percentage of participants